To further explore how BIM deletion polymorphisms cause resistance to TKIs in EGFR-mutant NSCLC, characterized several EGFR-mutant NSCLC cell lines (HCC827, RERF-Ad2-A2, HCC2279 and PC3), with or without the BIM deletion polymorphism that rendered them resistant to erlotinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.